JP2005502315A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502315A5
JP2005502315A5 JP2002574050A JP2002574050A JP2005502315A5 JP 2005502315 A5 JP2005502315 A5 JP 2005502315A5 JP 2002574050 A JP2002574050 A JP 2002574050A JP 2002574050 A JP2002574050 A JP 2002574050A JP 2005502315 A5 JP2005502315 A5 JP 2005502315A5
Authority
JP
Japan
Prior art keywords
gene
expression
mutation
mannheimia
gene product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002574050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502315A (ja
Filing date
Publication date
Priority claimed from US09/809,665 external-priority patent/US6790950B2/en
Application filed filed Critical
Publication of JP2005502315A publication Critical patent/JP2005502315A/ja
Publication of JP2005502315A5 publication Critical patent/JP2005502315A5/ja
Pending legal-status Critical Current

Links

JP2002574050A 2001-03-15 2002-01-17 抗菌性ワクチン組成物 Pending JP2005502315A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions
PCT/US2002/001971 WO2002075507A2 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010247585A Division JP2011097938A (ja) 2001-03-15 2010-11-04 抗菌性ワクチン組成物

Publications (2)

Publication Number Publication Date
JP2005502315A JP2005502315A (ja) 2005-01-27
JP2005502315A5 true JP2005502315A5 (enExample) 2006-01-05

Family

ID=25201919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002574050A Pending JP2005502315A (ja) 2001-03-15 2002-01-17 抗菌性ワクチン組成物
JP2010247585A Pending JP2011097938A (ja) 2001-03-15 2010-11-04 抗菌性ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010247585A Pending JP2011097938A (ja) 2001-03-15 2010-11-04 抗菌性ワクチン組成物

Country Status (18)

Country Link
US (2) US6790950B2 (enExample)
EP (1) EP1368456B1 (enExample)
JP (2) JP2005502315A (enExample)
AR (2) AR035745A1 (enExample)
AT (1) ATE500316T1 (enExample)
AU (1) AU2002240033B2 (enExample)
CA (2) CA2852293A1 (enExample)
CY (1) CY1112014T1 (enExample)
DE (1) DE60239318D1 (enExample)
DK (1) DK1368456T3 (enExample)
ES (1) ES2362041T3 (enExample)
MX (1) MXPA03008296A (enExample)
NZ (1) NZ528208A (enExample)
PE (1) PE20021008A1 (enExample)
PT (1) PT1368456E (enExample)
SI (1) SI1368456T1 (enExample)
TW (4) TWI335934B (enExample)
WO (1) WO2002075507A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060116041A (ko) * 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター, インコーポレイテッド 抗ウイルス細胞透過性ペプチド
CA2729818A1 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015066292A1 (en) * 2013-11-01 2015-05-07 Merial Limited Attenuated pasteurella multocidavaccines & methods of making & use thereof
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
SK55593A3 (en) 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
WO1994011024A1 (en) 1992-11-06 1994-05-26 Regents Of The University Of Minnesota Composition protective against p. multocida pasteurellosis infection
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
DE19502584C2 (de) 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
ATE419371T1 (de) * 1996-09-06 2009-01-15 Jensen Peter Ruhdal Verfahren zur verbesserung der herstellung eines erwünschten produktes aus einer zelle
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
KR20060116041A (ko) 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CA2379119A1 (en) * 1999-07-12 2001-01-18 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
EP1278768B1 (en) * 2000-04-27 2006-11-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens

Similar Documents

Publication Publication Date Title
Lau et al. A functional genomic analysis of type 3 Streptococcus pneumoniae virulence
Young et al. A bifunctional urease enhances survival of pathogenic Yersinia enterocolitica and Morganella morganii at low pH
Mattos-Graner et al. Cloning of the Streptococcus mutans gene encoding glucan binding protein B and analysis of genetic diversity and protein production in clinical isolates
Mascher et al. The Streptococcus pneumoniae cia regulon: CiaR target sites and transcription profile analysis
Wu et al. Identification of dipeptide repeats and a cell wall sorting signal in the fimbriae‐associated adhesin, Fap1, of Streptococcus parasanguis
Henze et al. Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance
US7824894B2 (en) Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
Dietz et al. Identification of target genes regulated by the two-component system HP166-HP165 of Helicobacter pylori
WO2002075507B1 (en) Anti-bacterial vaccine compositions
Berish et al. Molecular cloning and characterization of the structural gene for the major iron-regulated protein expressed by Neisseria gonorrhoeae.
AU2003234043A1 (en) Immunogenic sequences
JP2004065257A (ja) 特にグラム陽性菌に誘導型糖ペプチド耐性を付与するタンパク質
Ren et al. hgpB, a gene encoding a second Haemophilus influenzae hemoglobin-and hemoglobin-haptoglobin-binding protein
Harvey et al. A variable region within the genome of Streptococcus pneumoniae contributes to strain-strain variation in virulence
Beukes et al. Self-protection against cell wall hydrolysis in Streptococcus milleri NMSCC 061 and analysis of the millericin B operon
Han et al. Identification, molecular cloning, and sequence analysis of a deoxyribose aldolase in Streptococcus mutans GS-5
US5552273A (en) Polypeptides containing sequences characteristic of pyrrolidone carboxylyl peptidases, polynucleotides containing a sequence coding for such polypeptides, and their use, in particular for diagnostic purposes
Middendorf et al. Representational difference analysis identifies a strain-specific LPS biosynthesis locus in Bordetella spp.
Bereswill et al. Cloning and functional characterization of the genes encoding 3-dehydroquinate synthase (aroB) and tRNA-guanine transglycosylase (tgt) from Helicobacter pylori
Brüggemann et al. Clostridium botulinum
Wang et al. A UspA2H-negative variant of Moraxella catarrhalis strain O46E has a deletion in a homopolymeric nucleotide repeat common to uspA2H genes
EP1878439A2 (en) Actinobacillus pleuropneumoniae virulence genes
Peruzzi et al. Development of an integrative, lacZ transcriptional-fusion plasmid vector for Streptococcus mutans and its use to isolate expressed genes
CN121022889A (zh) 一种抗链霉素基因及其编码蛋白和应用
Ogunniyi et al. Regulation of pneumococcal surface proteins and capsule